Thermo Fisher To Acquire Clario Holdings For $8.875 Billion, Expands Digital Pharma Capabilities

Core Viewpoint - Thermo Fisher Scientific is acquiring Clario Holdings for $8.875 billion in cash, which is expected to enhance its digital and data capabilities in clinical research and drug development [1][3]. Group 1: Acquisition Details - The acquisition deal includes potential future earnouts and performance-based payments, with an initial cash payment at closing and additional payments scheduled for January 2027 and tied to performance results in 2026-2027 [1][4]. - Clario's platform has been instrumental in approximately 70% of FDA drug approvals over the past decade and is projected to generate around $1.25 billion in revenue for 2025 [2]. Group 2: Financial Impact - The acquisition is expected to be immediately accretive, adding 45 cents per share to adjusted EPS in the first year after closing and contributing around $175 million to adjusted operating income by year five [5]. - The company anticipates high single-digit growth for the acquired business and expects to realize $175 million in synergies by year five [5]. Group 3: Recent Earnings Performance - Thermo Fisher reported third-quarter 2025 sales of $11.12 billion, exceeding analyst expectations, and adjusted EPS of $5.79, also above consensus estimates [6]. - The company has raised its 2025 sales guidance to $44.1 billion-$44.5 billion, up from previous guidance, and expects annual profit per share to be in the range of $22.60-$22.86 [7].